American Association for Cancer Research
23266066cir180054-sup-196541_2_supp_5317889_pm9bw5.pdf (125.94 kB)

Figure S7 from Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer

Download (125.94 kB)
journal contribution
posted on 2023-04-03, 23:24 authored by Lukas W. Pfannenstiel, C. Marcela Diaz-Montero, Ye F. Tian, Joseph Scharpf, Jennifer S. Ko, Brian R. Gastman

Supplementary Figure 7. CD3+ CD8+ PD-1+ Tim-3+ T cells were FACS sorted from dissociated TC-1 tumor grown in C57BL/6 mice. Sorted T cells were then stimulated for 12h in vitro in 96-well plates coated with anti-CD3 and anti-CD28. Golgistoptm was added to the culture to arrest vessicle exocytosis. Cells were then permeabilized and stained for IL-10 and IFNγ or isotype control antibodies used at the same concentration.





Immune-checkpoint blockade enhances antitumor responses against cancers. One cancer type that is sensitive to checkpoint blockade is squamous cell carcinoma of the head and neck (SCCHN), which we use here to study limitations of this treatment modality. We observed that CD8+ tumor-infiltrating lymphocytes (TILs) in SCCHN and melanoma express excess immune checkpoints components PD-1 and Tim-3 and are also CD27−/CD28−, a phenotype we previously associated with immune dysfunction and suppression. In ex vivo experiments, patients' CD8+ TILs with this phenotype suppressed proliferation of autologous peripheral blood T cells. Similar phenotype and function of TILs was observed in the TC-1 mouse tumor model. Treatment of TC-1 tumors with anti–PD-1 or anti–Tim-3 slowed tumor growth in vivo and reversed the suppressive function of multi-checkpoint+ CD8+ TIL. Similarly, treatment of both human and mouse PD-1+ Tim-3+ CD8+ TILs with anticheckpoint antibodies ex vivo reversed their suppressive function. These suppressive CD8+ TILs from mice and humans expressed ligands for PD-1 and Tim-3 and exerted their suppressive function via IL10 and close contact. To model therapeutic strategies, we combined anti–PD-1 blockade with IL7 cytokine therapy or with transfer of antigen-specific T cells. Both strategies resulted in synergistic antitumor effects and reduced suppressor cell function. These findings enhance our understanding of checkpoint blockade in cancer treatment and identify strategies to promote synergistic activities in the context of other immunotherapies.

Usage metrics

    Cancer Immunology Research



    Ref. manager